EGFR and cancer: Our model achieved high prediction accuracy with generalizability and transferability through robust internal cross-study validation and external validation, enabling personalized prediction for resistance over different types of cancer cell lines and EGFR inhibitors, including gefitinib, erlotinib, afatinib, and cetuximab.